Outcome measures for central nervous system symptoms in myotonic dystrophy type 1: insights from a case-controlled study

被引：0
|
作者：
Hamilton, M. J. [1 ,2 ]
McLean, J. [3 ]
Cumming, S. [2 ]
Ballantyne, B. [1 ]
McGhie, J. [2 ]
Jampana, R. [3 ]
Longman, C. [1 ]
Evans, J. J.
Monckton, D. G. [2 ]
Farrugia, M. E.
机构：
[1] Queen Elizabeth Univ Hosp, West Scotland Clin Genet Serv, Glasgow G51 4TF, Lanark, Scotland
[2] Univ Glasgow, Coll Med Vet & Life Sci, Inst Mol Cell & Syst Biol, Glasgow G12 8QQ, Lanark, Scotland
[3] Queen Elizabeth Univ Hosp, Inst Neurol Sci, Dept Neuroradiol, Glasgow G51 4TF, Lanark, Scotland
来源：
NEUROMUSCULAR DISORDERS | 2018年 / 28卷
关键词：
D O I：
10.1016/S0960-8966(18)30321-3
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
D18
引用
收藏
页码：S11 / S11
页数：1
相关论文
共 50 条
  • [1] Patient Input to Inform the Development of Central Nervous System Outcome Measures in Myotonic Dystrophy
    White, Molly
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (05) : 1010 - 1017
  • [2] Patient Input to Inform the Development of Central Nervous System Outcome Measures in Myotonic Dystrophy
    Molly White
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 1010 - 1017
  • [3] Outcome Measures for Central Nervous System Evaluation in Myotonic Dystrophy Type 1 May Be Confounded by Deficits in Motor Function or Insight
    Hamilton, Mark J.
    McLean, John
    Cumming, Sarah
    Ballantyne, Bob
    McGhie, Josephine
    Jampana, Ravi
    Longman, Cheryl
    Evans, Jonathan J.
    Monckton, Darren G.
    Farrugia, Maria Elena
    FRONTIERS IN NEUROLOGY, 2018, 9
  • [4] Biomarkers for central nervous system involvement in Myotonic dystrophy type 1
    Varghese, A.
    Spendiff, S.
    Ross, A.
    Lochmueller, H.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S130 - S130
  • [5] Central Nervous System Involvement as Outcome Measure for Clinical Trials Efficacy in Myotonic Dystrophy Type 1
    Simoncini, Costanza
    Spadoni, Giulia
    Lai, Elisa
    Santoni, Lorenza
    Angelini, Corrado
    Ricci, Giulia
    Siciliano, Gabriele
    FRONTIERS IN NEUROLOGY, 2020, 11
  • [6] Responsiveness of outcome measures in myotonic dystrophy type 1
    Knak, Kirsten L.
    Sheikh, Aisha M.
    Witting, Nanna
    Vissing, John
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2020, 7 (08): : 1382 - 1391
  • [7] Central nervous system involvement in myotonic dystrophy type 2
    Spengos, K.
    Tsivgoulis, G.
    Gotsis, E.
    Toulas, P.
    Gialafos, E.
    Papadimas, G.
    Zambelis, T.
    Manta, P.
    JOURNAL OF NEUROLOGY, 2006, 253 : 105 - 106
  • [8] Cell type-specific abnormalities of central nervous system in myotonic dystrophy type 1
    Nakamori, Masayuki
    Shimizu, Hiroshi
    Ogawa, Kotaro
    Hasuike, Yuhei
    Nakajima, Takashi
    Sakurai, Hidetoshi
    Araki, Toshiyuki
    Okada, Yukinori
    Kakita, Akiyoshi
    Mochizuki, Hideki
    BRAIN COMMUNICATIONS, 2022, 4 (03)
  • [9] Intrarater reliability and validity of outcome measures in myotonic dystrophy type 1
    Knak, Kirsten L.
    Sheikh, Aisha M.
    Andersen, Henning
    Witting, Nanna
    Vissing, John
    NEUROLOGY, 2020, 94 (24) : E2508 - E2520
  • [10] Myotonic Dystrophy Type 1: A Case Study
    Hertza, J.
    Tyson, K.
    Northington, S.
    Loughan, A.
    Perna, R.
    Davis, A.
    ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2013, 28 (06) : 533 - 534
12345